{"id":"https://openalex.org/W2110067540","doi":"https://doi.org/10.1111/dom.12500","title":"Dapagliflozin\u2010induced weight loss affects 24\u2010week glycated haemoglobin and blood pressure levels","display_name":"Dapagliflozin\u2010induced weight loss affects 24\u2010week glycated haemoglobin and blood pressure levels","alternate_titles":[],"publication_year":2015,"publication_date":"2015-06-27","ids":{"openalex":"https://openalex.org/W2110067540","doi":"https://doi.org/10.1111/dom.12500","mag":"2110067540","pmid":"https://pubmed.ncbi.nlm.nih.gov/25997813"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12500","doi":"https://doi.org/10.1111/dom.12500","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12500","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2110067540"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041913215","display_name":"C. David Sj\u00f6str\u00f6m","orcid":"https://orcid.org/0000-0002-8380-9766","observed_orcids":["https://orcid.org/0000-0002-8380-9766"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"C. D. Sj\u00f6str\u00f6m","raw_affiliation_strings":["AstraZeneca  M\u00f6lndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca  M\u00f6lndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Hashemi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Hashemi","raw_affiliation_strings":["AstraZeneca  M\u00f6lndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca  M\u00f6lndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013087961","display_name":"Jennifer E. Sugg","orcid":"https://orcid.org/0000-0003-2208-077X","observed_orcids":["https://orcid.org/0000-0003-2208-077X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Sugg","raw_affiliation_strings":["Formerly AstraZeneca, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Formerly AstraZeneca, Wilmington, DE, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060577165","display_name":"Agata Ptaszynska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20089843","display_name":"Princeton University","ror":"https://ror.org/00hx57361","country_code":"US","type":"education","lineage":["https://openalex.org/I20089843"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Ptaszynska","raw_affiliation_strings":["Bristol-Myers Squibb; Princeton; NJ; USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb; Princeton; NJ; USA","institution_ids":["https://openalex.org/I20089843","https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031725659","display_name":"EVA K. JOHNSSON","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Johnsson","raw_affiliation_strings":["AstraZeneca  M\u00f6lndal Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca  M\u00f6lndal Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5041913215"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":5.8136,"has_fulltext":false,"cited_by_count":59,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.97122525,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"17","issue":"8","first_page":"809","last_page":"812"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8859999775886536},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9810000061988831},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9940000176429749},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.9319999814033508},{"id":"https://openalex.org/keywords/systolic-blood-pressure","display_name":"systolic blood pressure","score":0.9639999866485596},{"id":"https://openalex.org/keywords/diastolic-blood-pressure","display_name":"diastolic blood pressure","score":0.996999979019165},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.7730000019073486},{"id":"https://openalex.org/keywords/antihypertensive-effect","display_name":"antihypertensive effect","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.9810177683830261},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8722345232963562},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.747300922870636},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.7104235291481018},{"id":"https://openalex.org/C2909938374","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated haemoglobin","level":4,"score":0.5904169082641602},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5347520112991333},{"id":"https://openalex.org/C147583825","wikidata":"https://www.wikidata.org/wiki/Q620876","display_name":"Body weight","level":2,"score":0.4897794723510742},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4457222521305084},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4123794734477997},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.27216586470603943},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.1961698830127716},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.17498627305030823}],"mesh":[{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051247","descriptor_name":"Sodium-Glucose Transport Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.12500","doi":"https://doi.org/10.1111/dom.12500","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12500","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:25997813","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25997813","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1543297732","https://openalex.org/W1554005703","https://openalex.org/W1623518385","https://openalex.org/W1969335462","https://openalex.org/W2071477116","https://openalex.org/W2077636750","https://openalex.org/W2100650274","https://openalex.org/W2102758116","https://openalex.org/W2109225260","https://openalex.org/W2153839551","https://openalex.org/W2167245776","https://openalex.org/W2172193326","https://openalex.org/W2322658918"],"related_works":["https://openalex.org/W2322982687","https://openalex.org/W2544540254","https://openalex.org/W2324064174","https://openalex.org/W2086581579","https://openalex.org/W2616620312","https://openalex.org/W2620570497","https://openalex.org/W3035285166","https://openalex.org/W3013960079","https://openalex.org/W2319729347","https://openalex.org/W2748386152"],"abstract_inverted_index":{"The":[0],"aim":[1],"of":[2,50,72,80,110,116,123],"this":[3],"study":[4],"was":[5,65],"to":[6,46,53,78,114,135],"investigate":[7],"the":[8,48,59,81,93,117,124],"associations":[9],"between":[10],"dapagliflozin-mediated":[11,130],"reductions":[12,17,137],"in":[13,18,138],"body":[14],"weight":[15,51,131],"and":[16,22,55,88,102,121,140],"glycated":[19],"haemoglobin":[20],"(HbA1c)":[21],"blood":[23,56,90,141],"pressure.":[24,142],"Data":[25],"were":[26,97],"pooled":[27],"from":[28],"seven":[29],"studies":[30],"evaluating":[31],"dapagliflozin":[32,76],"10":[33],"mg":[34],"as":[35],"monotherapy":[36],"or":[37],"combination":[38],"therapy":[39],"over":[40],"24":[41],"weeks.":[42],"Using":[43],"linear":[44],"regression":[45],"estimate":[47,61],"contribution":[49],"loss":[52,71,109,132],"HbA1c":[54,63,83,139],"pressure":[57,91],"reductions,":[58],"\u03b2-value":[60,94],"for":[62],"(%)/kg":[64],"0.028":[66],"(p":[67,99,104],"<":[68,100,105],"0.0001).":[69],"Weight":[70,108],"2":[73,111],"kg":[74,112],"with":[75],"contributed":[77,113],"6%":[79],"total":[82],"reduction.":[84,127],"For":[85],"systolic":[86],"(SBP)":[87],"diastolic":[89],"(DBP),":[92],"(mmHg/kg)":[95],"estimates":[96],"0.606":[98],"0.0001)":[101],"0.253":[103],"0.0001),":[106],"respectively.":[107],"28%":[115],"overall":[118,125,136],"SBP":[119],"reduction,":[120],"24%":[122],"DBP":[126],"In":[128],"conclusion,":[129],"may":[133],"contribute":[134]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2110067540","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
